Details
Stereochemistry | RACEMIC |
Molecular Formula | C20H20ClN5O3S2 |
Molecular Weight | 477.988 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(CC1)C(=O)OC2N(C(=O)C3=C2SCCS3)C4=CC=C5C=CC(Cl)=NC5=N4
InChI
InChIKey=RMXOUBDDDQUBKD-UHFFFAOYSA-N
InChI=1S/C20H20ClN5O3S2/c1-24-6-8-25(9-7-24)20(28)29-19-16-15(30-10-11-31-16)18(27)26(19)14-5-3-12-2-4-13(21)22-17(12)23-14/h2-5,19H,6-11H2,1H3
Molecular Formula | C20H20ClN5O3S2 |
Molecular Weight | 477.988 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Suriclone is a dithiinopyrrole derivative patented by Rhone-Poulenc S. A. as a sedative and anxiolytic drug. The mechanism of action by which suriclone produces it's sedative and anxiolytic effects is by modulating GABAA receptors, although suriclone is more subtype-selective than most benzodiazepines. In clinical trials, Suriclone shows a significant anxiolytic effect. The most common adverse reaction was dizziness.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7910470
0.1, 0.2 and 0.4 mg
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:19:49 GMT 2023
by
admin
on
Fri Dec 15 18:19:49 GMT 2023
|
Record UNII |
LNC9G689VR
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C28197
Created by
admin on Fri Dec 15 18:19:49 GMT 2023 , Edited by admin on Fri Dec 15 18:19:49 GMT 2023
|
||
|
NCI_THESAURUS |
C29710
Created by
admin on Fri Dec 15 18:19:49 GMT 2023 , Edited by admin on Fri Dec 15 18:19:49 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
53813-83-5
Created by
admin on Fri Dec 15 18:19:49 GMT 2023 , Edited by admin on Fri Dec 15 18:19:49 GMT 2023
|
PRIMARY | |||
|
SUB10782MIG
Created by
admin on Fri Dec 15 18:19:49 GMT 2023 , Edited by admin on Fri Dec 15 18:19:49 GMT 2023
|
PRIMARY | |||
|
C037283
Created by
admin on Fri Dec 15 18:19:49 GMT 2023 , Edited by admin on Fri Dec 15 18:19:49 GMT 2023
|
PRIMARY | |||
|
SURICLONE
Created by
admin on Fri Dec 15 18:19:49 GMT 2023 , Edited by admin on Fri Dec 15 18:19:49 GMT 2023
|
PRIMARY | |||
|
C96876
Created by
admin on Fri Dec 15 18:19:49 GMT 2023 , Edited by admin on Fri Dec 15 18:19:49 GMT 2023
|
PRIMARY | |||
|
m949
Created by
admin on Fri Dec 15 18:19:49 GMT 2023 , Edited by admin on Fri Dec 15 18:19:49 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL2105561
Created by
admin on Fri Dec 15 18:19:49 GMT 2023 , Edited by admin on Fri Dec 15 18:19:49 GMT 2023
|
PRIMARY | |||
|
DTXSID20866362
Created by
admin on Fri Dec 15 18:19:49 GMT 2023 , Edited by admin on Fri Dec 15 18:19:49 GMT 2023
|
PRIMARY | |||
|
40903
Created by
admin on Fri Dec 15 18:19:49 GMT 2023 , Edited by admin on Fri Dec 15 18:19:49 GMT 2023
|
PRIMARY | |||
|
100000082987
Created by
admin on Fri Dec 15 18:19:49 GMT 2023 , Edited by admin on Fri Dec 15 18:19:49 GMT 2023
|
PRIMARY | |||
|
4701
Created by
admin on Fri Dec 15 18:19:49 GMT 2023 , Edited by admin on Fri Dec 15 18:19:49 GMT 2023
|
PRIMARY | |||
|
258-794-1
Created by
admin on Fri Dec 15 18:19:49 GMT 2023 , Edited by admin on Fri Dec 15 18:19:49 GMT 2023
|
PRIMARY | |||
|
LNC9G689VR
Created by
admin on Fri Dec 15 18:19:49 GMT 2023 , Edited by admin on Fri Dec 15 18:19:49 GMT 2023
|
PRIMARY | |||
|
104355-41-1
Created by
admin on Fri Dec 15 18:19:49 GMT 2023 , Edited by admin on Fri Dec 15 18:19:49 GMT 2023
|
SUPERSEDED |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |